A Phase I, Pharmacologic and Biologic Study of Col-3 (NSC683551) Administered on a 28-Day Oral Dosing Schedule in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2012
At a glance
- Drugs Incyclinide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Sep 2005 New trial record.